Impact of new consent procedures on uptake of the schools-based Human Papillomavirus (HPV) vaccination programme by Fisher, Harriet et al.
                          Fisher, H., Hickman, M., Ferrie, J., Evans, K., Bell, M., Yates, J.,
Roderick, M., Reynolds, R., MacLeod, J., & Audrey, S. (2020). Impact
of new consent procedures on uptake of the schools-based Human
Papillomavirus (HPV) vaccination programme. Journal of Public
Health, [fdaa164]. https://doi.org/10.1093/pubmed/fdaa164
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1093/pubmed/fdaa164
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Oxford University
Press at https://doi.org/10.1093/pubmed/fdaa164. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
1
© The Author(s) 2020. Published by Oxford University Press on behalf of Faculty of Public Health.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
Harriet Fisher, Senior Research Associate
Matthew Hickman, Professor in Public Health and Epidemiology
Joanne Ferrie, Screening and Immunisations Coordinator
Karen Evans, Head of School Nursing and Specialist Nursing Services
Michael Bell, Patient and Public Involvement Facilitator
Julie Yates, Consultant in Public Health
Marion Roderick, Specialist Registrar Paediatric Immunology & Infectious Disease
Rosy Reynolds, Senior Research Associate
John MacLeod, Professor in Clinical Epidemiology and Primary Care
Suzanne Audrey, Senior Research Fellow in Public Health
Journal of Public Health | pp. 1–8 | doi:10.1093/pubmed/fdaa164
Impact of new consent procedures on uptake of the
schools-based human papillomavirus (HPV) vaccination
programme
Harriet Fisher1, Matthew Hickman1, Joanne Ferrie2, Karen Evans 3, Michael Bell4,
Julie Yates2, Marion Roderick5, Rosy Reynolds1, John MacLeod1, Suzanne Audrey1
1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
2Screening and Immunisations South West, Public Health England, Tauton, UK
3Sirona Care & Health, Bristol and South Gloucestershire, Bristol, UK
4Bristol Biomedical Research Centre and NIHR CLAHRC West, Bristol, UK
5Department of Paediatric Immunology & Infectious Disease, Bristol Royal Hospital for Children, Bristol, UK
Address correspondence to Harriet Fisher, E-mail: Harriet.Fisher@bristol.ac.uk
ABSTRACT
Background Local policy change initiating new consent procedures was introduced during 2017–2018 for the human papillomavirus (HPV)
vaccination programme year in two local authorities in the south–west of England. This study aims to assess impact on uptake and inequalities.
Methods Publicly available aggregate and individual-level routine data were retrieved for the programme years 2015–2016 to 2018–2019.
Statistical analyses were undertaken to show: (i) change in uptake in intervention local authorities in comparison to matched local authorities
and (ii) change in uptake overall, and by local authority, school type, ethnicity and deprivation.
Results Aggregate data showed uptake in Local Authority One increased from 76.3% to 82.5% in the post-intervention period (risk
difference: 6.2% P = 0.17), with a difference-in-differences effect of 11.5% (P = 0.03). There was no evidence for a difference-in-differences
effect in Local Authority Two (P = 0.76). Individual-level data showed overall uptake increased post-intervention (risk difference: +1.1%,
P = 0.05), and for young women attending school in Local Authority One (risk difference: 2.3%, P < 0.01). No strong evidence for change by
school category, ethnic group and deprivation was found.
Conclusion Implementation of new consent procedures can improve and overcome trends for decreasing uptake among matched local
authorities. However, no evidence for reduction in inequalities was found.
Implications and discussion The new consent procedures increased uptake in one of the intervention sites and appeared to overcome trends
for decreasing uptake in matched sites. There are issues in relation to the quality of data which require addressing.
Keywords HPV vaccination programme, adolescents, consent, policy, quasi experimental study design
Introduction
The English Human Papillomavirus (HPV) vaccination
programme aims to prevent mortality and morbidity from
HPV-related diseases, including cervical cancer. Since intro-
duction in 2008, high coverage has been achieved, with
over 10 million vaccine-eligible young women receiving
immunization against HPV.1 Recent evidence highlights the
potential for HPV vaccination programmes to eliminate
cervical cancer.2,3 Based on emerging evidence for cost-
effectiveness, in 2019–2020 the HPV vaccination programme
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Despite overall high vaccination rates in England, there are
wide variations in uptake in different local authorities from
67.8% to 95.3%.4 Within the overall uptake rate, there are
pockets of significantly lower uptake amongst some popula-
tions—such as minority ethnic groups and young people edu-
cated in alternative provider settings (e.g. specialist schools for
young people with learning disabilities, pupil referral units).5
These inequalities in uptake have the potential to widen pre-
existing disparities in the incidence of HPV-related cancers by
ethnicity.6
Barriers to uptake of the English HPV vaccination
programme are complex, and include sociocultural beliefs and
levels of prioritization for young women to be vaccinated.7
The requirement for written parental consent has also
been shown to be a barrier to vaccination.8 In England,
the legal framework allows young people to be vaccinated
without parental consent provided they are deemed ‘Gillick-
competent’.9 However, earlier studies show adolescent self-
consent was not widely implemented due to local policies and
procedures and reluctance from healthcare professionals.10,11
The introduction of local policies which support alter-
native strategies of obtaining consent, including adolescent
self-consent procedures and verbal consent from parents,
has the potential to increase uptake of the HPV vaccination
programme. The current study was undertaken as a wider
programme of research to explore the practicality and accept-
ability of implementing new consent procedures in two local
authorities in the south–west of England.12 Specifically, this
study examines the impact of the new consent procedures on
uptake of the HPV vaccination programme. Findings related
to the acceptability of the new consent procedures have been
submitted for publication and will be reported shortly.
We use a quasiexperimental study design to:
(i) compare HPV vaccination uptake in the intervention sites
with other sites in England where no such intervention
took place; and
(ii) compare uptake of the HPV vaccination programme
pre- and post-implementation of the consent procedures
in the intervention sites overall, and by local authority,
school type, ethnic group and deprivation quintile.
Methods
Intervention sites
In response to concerns about low uptake rates in the inter-
vention sites, staff at PHE (South West) developed a ‘South
West Template Pathway on Self Consent for School Aged
Immunisations’. The aim is to support provider organizations
in implementing a self-consent process to support young
people to easily access vaccines, support immunizers to feel
confident about self-consent and to improve the uptake of
immunizations. This policy change was introduced in the two
local authorities (comprising the intervention sites) in the
south–west of England in the 2016–2017 HPV vaccination
programme.
The intervention
The published study protocol provides a detailed description
of the new consent procedures for vaccination in the school-
setting.12 The study was undertaken when the English vacci-
nation programme was delivered routinely to young women
only. In brief, prior to the intervention, young women would
only receive the HPV vaccine in the school-setting if a writ-
ten, affirmative parental consent form had been returned to
the immunization team and the young woman provided her
assent. Policies for consent pathways are locally determined
by each provider and are not consistent leading to different
interpretation of guidelines and variation across the country.
Under the new procedures, where written parental consent is
not received the immunization team make telephone calls to
seek parental verbal consent during the vaccination session.
Additionally, if parents cannot be contacted during the vacci-
nation session, young women considered ‘Gillick-competent’
by the immunization team can self-consent if they confirm
that they have discussed the vaccine with their parents and it
would not cause a problem at home if they were vaccinated
without written or verbal parental consent. Young women
who do not receive the vaccine on the day are provided with
written information about community catch-up clinics.
Change in uptake in intervention sites from
comparison local authorities in England
Data reporting for uptake of the English HPV vaccination
programme is mandatory.13 Data related to the eligible popu-
lation and the number of doses administered are submitted to
Public Health England via ImmForm annually.14 These data,
aggregated at the local authority level, were retrieved from
an openly available data source.15 To select local authorities
with similar characteristics to the intervention sites for com-
parison, publicly available secondary school-level data were
obtained on ethnicity and eligibility for Free School Meals (a
measure of deprivation) during the last 6 years.16
Local authorities were assigned to tertiles for the following
variables: (i) percentage of young women receiving at least
one dose of the HPV vaccine in the 2016–2017 HPV vaccina-
tion programme (as it was the most recent data available prior
to the change to consent policy); (ii) percentage of secondary
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of childhood deprivation); and (iii) percentage of secondary
school population classified as White British.
Four local authorities matched identically during the 2016–
2017 HPV vaccination programme to Local Authority One in
terms of vaccination uptake, Free School Meals, and ethnicity
and were selected as comparative local authorities for analysis.
The same procedure was followed to match an additional
nine local authorities with characteristics corresponding to
those for Local Authority Two. The numbers of local author-
ities matched differed by intervention site due to different
underlying population characteristics of Local Authority One
and Two.
Uptake of HPV vaccination programme pre- and
post-intervention
Prior to study initiation, permission was sought from Sirona
Healthcare and InHealth Intelligence, the organizations with
responsibility for the data. The data provided covered the two
local authorities that implemented the new consent proce-
dures and covered urban or rural/urban areas in the south–
west of England. All records relating to young women eligible
for vaccination during the intervention period (born between
1 September 2001 and 31 August 2006) who attended school
within the geographical boundaries were retrieved.
In the UK, the Child Health Information System holds
demographic and vaccination-related records for each young
person registered with a family practice. Using a computerized
search, the following data fields were extracted from records:
(i) partial date of birth; (ii) postcode; (iii) ethnicity; (iv) dates
and location HPV vaccination administered; and (v) name and
identifying code of school.
Originally, we planned to seek variables related to receipt
of childhood vaccinations as a proxy for parental vaccina-
tion beliefs.5 Following introduction of the new European
Union General Data Protection Regulation (GDPR),17 inter-
pretation of information governance legislation by the data
providers suggested that this variable could only be provided
where individual consent was obtained from general practices
identified as the data custodian of this variable—which would
be too costly and onerous to obtain—so these data available
on Child Health Information System were not extracted for
this analysis.
School code was used to assign the local authority responsi-
ble for delivery of the HPV vaccine. Partial date of birth was
used to allocate the programme year when young women were
eligible to receive the HPV vaccine. The following school type
categories were applied to each record: (i) comprehensive,
non-fee-paying; (ii) private, fee-paying; and (iii) alternative
education provider (specialist schools for students with sig-
nificant additional needs, pupil referral units, young offender
units, hospital education service and educated at home).
Individual records were classified as ‘received HPV on time’
if there was a record of at least one HPV vaccine dose admin-
istered in the programme year in which the young woman was
eligible. Postcodes from individual records were linked to the
corresponding lower super output area. A deprivation score
was assigned using the Index of Multiple Deprivation 201918
and the sample analysed as quintiles. Ethnicity was grouped
as: (i) White British; (ii) Black/Black British; (iii) Asian/British
Asian; (iv) Mixed background; (v) Other ethnic group; and (vi)
Unknown.
The records of young women were excluded from analyses
if the relevant school code was either missing, or invalid (e.g.
primary school). In the intervention local authorities, parents
are routinely asked antenatally to provide information on
ethnicity. Although some parents may refuse to provide this
information, missing antenatal ethnicity data may represent
young women who were born outside local authority bound-
aries (e.g. immigrant populations) but are now living and/or
attending school in the area. For these reasons, data were not
excluded on the basis of unknown ethnicity.
Analysis
Change in intervention sites from comparison local
authorities in England
The dataset was stratified by pre-intervention (programme
years 2015–2016 to 2016–2017) and post-intervention study
period (programme years 2017–2018 to 2018–2019). The
mean number of young women eligible for vaccination and
percentage of young women who received the first dose of
the HPV vaccine on time was presented overall for Eng-
land, and separately for the intervention local authorities and
comparison local authorities. To test whether there has been
an increase in the uptake of the HPV vaccination after the
intervention, the risk difference (difference in two proportions
and tests of null hypothesis that there has been no change in
uptake) was calculated. The ‘difference in differences’ statis-
tical approach was used to measure differences of uptake of
the HPV vaccine between the intervention and comparator
groups occurring over time.19
Uptake of HPV vaccination programme pre- and
post-intervention
Using individual-level data rather than aggregate data, the risk
difference was calculated to test whether there has been an
increase in the uptake in the intervention local authorities
from the pre-intervention to the post-intervention period. To
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N % (SE) P-value N % (SE) P-value % (SE) P-value
England overall 587,610 87.5 (0.3) 620,878 87.1 (0.3) −0.4 (0.4) 0.36
Intervention site: Local Authority One 2022 Mean (0.1) 2362 Mean (1.7) +6.2 (1.7) 0.17
Comparator local authorities 1367 85.2 (1.6) 1504 79.9 (1.6) −5.3 (2.3) 0.04
Difference: Local Authority One-comparator −8.8 (3.4) 0.02 2.6 (3.4) 0.45 +11.5 (4.8)∗ 0.03
Intervention site: Local Authority Two 1221 84.8 (2.4) 1381 87.3 (0.1) +2.4 (2.4) 0.49
Comparator local authorities 2733 87.1 (0.6) 2809 88.2 (1.2) +1.0 (1.3) 0.43
Difference: Local Authority Two-Comparator −2.3 (2.9) 0.42 −0.9 (2.9) 0.76 +1.5 (3.6)∗ 0.72
Pre-intervention period, 2015–2016 to 2016–2017; post-intervention period, 2017–2018 to 2018–2019; HPV, human papillomavirus; SE, standard error.
∗Difference-in-differences.
in health inequalities, risk differences were also calculated
to assess whether uptake differed by local authority, school
category, ethnic group and deprivation quintile.
Measures of effect are measured as risk differences,
difference-in-differences and presented with the correspond-
ing standard errors (SE) and P-values. All analyses were
performed with Stata statistical package, release 15 (Stata
Corp, College Station, TX).
Results
Change in intervention sites from comparison local
authorities in England
Nationally, the uptake of the HPV vaccine remained stable
from the pre-intervention to the post-intervention period
(87.1% versus 87.5%, P = 0.36). Overall, aggregate data
showed uptake in Local Authority One was 76.3% in the
pre-intervention period and 82.5% in the post-intervention
period (risk difference: 6.2%, P = 0.17). In the matched local
authorities, change to uptake was from 85.2% to 79.9% in
the pre- to post-intervention period (risk difference: −5.3%,
P = 0.04), giving a difference-in-differences measure of effect
as 11.5% (P = 0.03). In Local Authority Two, there was
no change in uptake from the pre- to the post-intervention
period from 84.8% to 87.3% (risk difference: 2.4%, P = 0.32).
There was no change in the matched local authorities (risk
difference: 1.0%, P = 0.93), and the overall difference-in-
differences measure of effect was 1.5% (P = 0.57) (Table 1).
Uptake of HPV vaccination programme pre- and
post-intervention
Records related to 14,501 young women registered with a
family practitioner and eligible for routine HPV vaccination
during the study period were extracted. Individual records
were excluded if the school identifying code was absent or
invalid (n = 784, 5.4%), the date of birth was invalid (n = 63,
0.4%), or partial postcode was missing or invalid (n = 364,
2.5%).
Of the 13,290 eligible for vaccination during the study
period, the majority attended school in Local Authority One
(n = 8236, 62.0%), attended comprehensive, non-fee-paying
schools (n = 11,945, 89.9%), and were classified as White
British (n = 9085, 68.4%; Table 2).
Overall, uptake increased from 87.9% in the pre-
intervention period to 89.0% in the post-intervention period
(risk difference: 1.1%, P = 0.05). There was evidence for an
intervention effect for young women attending schools in
Local Authority One (risk difference: 2.3%, P < 0.01), but no
such effect in Local Authority Two (risk difference: −0.7%,
0.34). There was weaker evidence to support an increase in
the proportion of young women who received the first dose
of the HPV vaccine among those who attended private, fee-
paying schools (risk difference: 4.0%, P = 0.09) and for those
classified as White British (risk difference: 1.0%, P = 0.08).
Although there was no strong evidence for an intervention
effect, the proportion of young women who received
the first dose of the HPV vaccine remained substantially
lower among those attending alternative education provider
settings than the other school categories. For example, in
the post-intervention period this was 73.5% (95% CI: 65.3–
81.6%) compared to 89.7% (95% CI: 88.9–90.4%) in the
comprehensive, non-fee-paying school category. There was
no evidence for an effect by deprivation quintile (Table 2).
Discussion
Main findings
This study reports the impact of new consent procedures








niversity of Bristol Library user on 27 Septem
ber 2020
IMPACT OF NEW CONSENT PROCEDURES ON UPTAKE OF THE SCHOOLS-BASED HPV VACCINATION PROGRAMME 5
Table 2 Timely HPV vaccination uptake pre- and post-intervention period∗
Pre-intervention Post-intervention
Overall HPV vaccine dose one uptake HPV vaccine dose one uptake Risk difference P-value
N (%) n % (95% CI) n % (95% CI) %
Overall 13,290 (100.0) 6343 87.9 (87.1–88.7) 6947 89.0 (88.3–89.7) 1.1 0.05
Intervention sites
Local Authority One 8236 (62.0) 3878 85.0 (83.8–86.1) 4358 87.3 (86.3–88.3) +2.3 <0.01
Local Authority Two 5054 (38.0) 2465 92.5 (91.5–93.6) 2589 91.8 (90.8–92.9) −0.7 0.34
School category
Comprehensive, non-fee-paying 11,945 (89.9) 5677 88.9 (88.1–89.8) 6268 89.7 (88.9–90.4) +0.8 0.17
Private, fee-paying 1042 (7.8) 476 80.5 (79.7–85.9) 556 84.5 (81.5–87.4) +4.0 0.09
Alternative education providers 303 (2.3) 190 76.8 (70.8–82.8) 113 73.5 (65.3–81.6) −3.4 0.51
Ethnic group
White British 9085 (68.4) 4319 92.3 (91.5–93.1) 4766 93.2 (92.5–94.0) +1.0 0.08
Black/Black British 28 (0.2) 12 58.3 (30.4–86.2) 16 75.0 (53.7–96.2) 16.7 0.35
Asian/British Asian 646 (4.9) 302 89.1 (85.6–92.6) 344 90.1 (87.0–93.3) +1.0 0.66
Mixed background 24 (0.2) 8 62.5 (29.0–96.0) 16 62.5 (38.8–86.2) 0.0 1.00
Other ethnic group 355 (2.7) 168 85.1 (79.7–90.5) 187 80.7 (75.1–86.4) −4.4 0.28
Unknown 3152 (23.7) 1534 76.0 (73.9–78.1) 1618 77.6 (75.5–79.6) +1.6 0.30
Deprivation quintile
Least Deprived 2646 (19.9) 1298 91.4 (89.8–92.9) 1348 91.6 (90.1–93.1) −0.2 0.82
2 2632 (19.8) 1253 91.7 (90.2–93.2) 1379 92.6 (91.2–94.0) +0.9 0.39
3 3666 (20.1) 1263 89.8 (88.1–91.5) 1403 90.7 (89.2–92.3) 0.9 0.41
4 2660 (20.0) 1264 84.0 (82.0–86.0) 1396 86.2 (84.4–88.0) +2.2 0.12
Most deprived 2686 (20.2) 1264 82.6 (80.5–84.7) 1421 84.0 (82.1–85.9) +1.4 0.33
∗Pre-intervention period, 2015–2016 to 2016–2017; Post-intervention period, 2017–2018 to 2018–2019; HPV, human papillomavirus; CI, confidence
intervals.
to young women. Analyses on publicly available aggregate
data were undertaken to compare trends of uptake in local
authorities with similar characteristics. These suggested that
the difference-in-differences effect of implementation of the
new consent procedures in the local authority with lower
uptake was ∼12%. Our findings from individual-level dataset
obtained from the Child Health Information System suggest
there was a small overall increase in the proportion of young
women receiving immunization against HPV during the inter-
vention period. There was, however, evidence that uptake
increased by ∼2% for young women attending schools in
Local Authority One.
What is already known on this topic
The analyses suggest that the implementation of new consent
procedures in Local Authority One could be overcoming
trends towards lower uptake observed in the matched local
authorities. It is currently unknown the reasons for trends
in decreasing uptake among these local authorities or why
this effect was not observed in Local Authority Two. Despite
largely positive public attitudes to vaccination,20 recent calls
have been made to tackle negative misconceptions of vaccines
and limit health misinformation circulating in social media.21
It is possible that miscommunication of HPV vaccine mes-
sages may have influenced trends in uptake among these local
authorities.
Substantially lower uptake of the HPV vaccine by young
women in alternative education settings, who may have intel-
lectual disabilities, physical health problems or behavioural
issues preventing them from attending mainstream school
settings, is a concern. These young women are considered
more vulnerable and are already known to experience adverse
outcomes across multiple health and social domains. Greater
understanding of the barriers to uptake of the HPV vaccina-
tion programme by these young women could help improve
access and address inequalities in uptake.
What this study adds
The different effect sizes on data obtained from different
data sources suggests the results may be influenced by data
quality issues. In the analyses comprising individual-level data,
for example, almost 800 (4.5%) records were excluded from
analysis on the basis that the school assigned to the record
was invalid (e.g. primary school). It is likely that a significant
proportion of these young women are no longer resident
within the local authority boundaries (e.g. moved abroad or
to a different local authority) and would therefore not have
been eligible for vaccination by the immunization team.
Despite the denominator of both data sources being
similar, recorded uptake of the HPV vaccination differed
by data sources. This has several important implications
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not accurately reflect actual uptake. Secondly, organizations
responsible for delivery of vaccination programmes may face
a loss of income if actual performance and activity is better
than the data suggest. Finally, this could negatively impact
morale of immunization teams responsible for delivery of
the programme.
Demographic growth of vaccine-eligible young women in
the intervention local authorities was observed during the
intervention period (local authority one: 480; local authority
two: 124). During the study period, ∼360 additional young
women were eligible for the HPV vaccine each year which
would impact the capacity of the immunization team to
deliver the programme as efficiently. Further, lobby groups
targeted school leaders with anti-vaccination messages prior
to the 2017–2018 programme being delivered. The impact
this had on vaccination decision-making amongst families is
unknown.
Recently, Public Health England issued updated guidance
for healthcare professionals which supports the use of parent
verbal consent and adolescent self-consent as strategies
to maximize uptake and reduce catch-up sessions.22 An
updated data collection tool for the new universal HPV
vaccination programme (introduced in 2019–2020) will
seek non-mandatory information relating to distribution of
consent forms, forms returned, verbal consent and refusals.23
This will help provide further evidence on a national basis of
the extent to which changes to immunization consent policies
can improve young people’s access to, and ultimately uptake
of, the HPV vaccination programme. The process evaluation
undertaken as part of this study will report the acceptability of
different methods of obtaining consent from the perspectives
of young women, parents and professionals involved with the
HPV vaccination programme.
Limitations of this study
Our study utilized routinely collected vaccination data elim-
inating the risk of recall and selection bias. The population-
based data relates to vaccinations delivered in school and com-
munity settings to all young women registered with a general
practice eligible for routine HPV vaccination during the study
period. Although the data for this study relates to females only,
the findings are also likely to be relevant to the universal HPV
vaccination programme as immunization teams’ consent pro-
cedures will not differentiate young people by gender.
Some limitations to the study warrant discussion. This
study used a quasiexperimental design as a randomized con-
trolled trial was not possible or practical. This is especially
relevant for health policies and programmes targeted at the
population level.24 One of our analyses used a pre- and
post-intervention design, without a comparator group. For
this reason, we also undertook analyses using national aggre-
gate data to compare uptake in the intervention areas with
trends in uptake nationally. We matched local authorities to
our intervention sites according to aggregate measures of
uptake of the HPV vaccination programme, deprivation and
ethnicity. There may be other unmeasured characteristics of
the population of the local authorities which could also be
influential (e.g. perceptions of adolescent autonomy).
As the study relied on routinely collected information, we
did not have access to individual-level measures of socioe-
conomic status. The study may have been underpowered
to detect possible non-trivial differences pre- and post-
intervention by ethnicity and school category. We relied
on area-based measures of deprivation and therefore our
study findings may be subject to ecological fallacy. An issue,
common to all routinely collected data, is the possibility of
data input errors and missing data. We excluded almost 5% of
the data as the information related to school was out-of-date.
Conclusion
Implementation of new consent procedures appeared to
overcome trends for decreasing uptake in one of the
intervention sites. However, there was no evidence for an
absolute increase or reduction in inequalities in uptake. Data
quality issues that appear to underreport uptake should be
investigated further. Lower uptake among young women in
alternative education settings needs addressing.
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